Breaking News
May 3, 2019 - Vaping and Smoking May Signal Greater Motivation to Quit
May 3, 2019 - Dementia looks different in brains of Hispanics
May 3, 2019 - Short-Staffed Nursing Homes See Drop In Medicare Ratings
May 3, 2019 - Study of teens with eating disorders explores how substance users differ from non-substance users
May 3, 2019 - Scientists develop new video game that may help in the study of Alzheimer’s
May 3, 2019 - Arc Bio introduces Galileo Pathogen Solution product line at ASM Clinical Virology Symposium
May 3, 2019 - Cornell University study uncovers relationship between starch digestion gene and gut bacteria
May 3, 2019 - How to Safely Use Glucose Meters and Test Strips for Diabetes
May 3, 2019 - Anti-inflammatory drugs ineffective for prevention of Alzheimer’s disease
May 3, 2019 - Study tracks Pennsylvania’s oil and gas waste-disposal practices
May 3, 2019 - Creating a better radiation diagnostic test for astronauts
May 3, 2019 - Vegans are often deficient in these four nutrients
May 3, 2019 - PPDC announces seed grants to develop medical devices for children
May 3, 2019 - Study maps out the frequency and impact of water polo head injuries
May 3, 2019 - Research on Reddit identifies risks associated with unproven treatments for opioid addiction
May 3, 2019 - Good smells may help ease tobacco cravings
May 3, 2019 - Medical financial hardship found to be very common among people in the United States
May 3, 2019 - Researchers develop multimodal system for personalized post-stroke rehabilitation
May 3, 2019 - Study shows significant mortality benefit with CABG over percutaneous coronary intervention
May 3, 2019 - Will gene-editing of human embryos ever be justifiable?
May 3, 2019 - FDA Approves Dengvaxia (dengue vaccine) for the Prevention of Dengue Disease in Endemic Regions
May 3, 2019 - Why Tonsillitis Keeps Coming Back
May 3, 2019 - Fighting the opioid epidemic with data
May 3, 2019 - Maggot sausages may soon be a reality
May 3, 2019 - Deletion of ATDC gene prevents development of pancreatic cancer in mice
May 2, 2019 - Targeted Therapy Promising for Rare Hematologic Cancer
May 2, 2019 - Alzheimer’s disease is a ‘double-prion disorder,’ study shows
May 2, 2019 - Reservoir bugs: How one bacterial menace makes its home in the human stomach
May 2, 2019 - Clinical, Admin Staff From Cardiology Get Sneak Peek at Epic
May 2, 2019 - Depression increases hospital use and mortality in children
May 2, 2019 - Vicon and NOC support CURE International to create first gait lab in Ethiopia
May 2, 2019 - Researchers use 3D printer to make paper organs
May 2, 2019 - Viral infection in utero associated with behavioral abnormalities in offspring
May 2, 2019 - U.S. Teen Opioid Deaths Soaring
May 2, 2019 - Opioid distribution data should be public
May 2, 2019 - In the Spotlight: “I’m learning every single day”
May 2, 2019 - 2019 Schaefer Scholars Announced
May 2, 2019 - Podcast: KHN’s ‘What The Health?’ Bye-Bye, ACA, And Hello ‘Medicare-For-All’?
May 2, 2019 - Study describes new viral molecular evasion mechanism used by cytomegalovirus
May 2, 2019 - SLU study suggests a more equitable way for Medicare reimbursement
May 2, 2019 - Scientists discover first gene involved in lower urinary tract obstruction
May 2, 2019 - Researchers identify 34 genes associated with increased risk of ovarian cancer
May 2, 2019 - Many low-income infants receive formula in the first few days of life, finds study
May 2, 2019 - Global study finds high success rate for hip and knee replacements
May 2, 2019 - Taking depression seriously: What is it?
May 2, 2019 - With Head Injuries Mounting, Will Cities Put Their Feet Down On E-Scooters?
May 2, 2019 - Scientists develop small fluorophores for tracking metabolites in living cells
May 2, 2019 - Study casts new light into how mothers’ and babies’ genes influence birth weight
May 2, 2019 - Researchers uncover new brain mechanisms regulating body weight
May 2, 2019 - Organ-on-chip systems offered to Asia-Pacific regions by Sydney’s AXT
May 2, 2019 - Adoption of new rules drops readmission penalties against safety net hospitals
May 2, 2019 - Kids and teens who consume zero-calorie sweetened beverages do not save calories
May 2, 2019 - Improved procedure for cancer-related erectile dysfunction
May 2, 2019 - Hormone may improve social behavior in autism
May 2, 2019 - Alzheimer’s disease may be caused by infectious proteins called prions
May 2, 2019 - Even Doctors Can’t Navigate Our ‘Broken Health Care System’
May 2, 2019 - Study looks at the impact on criminal persistence of head injuries
May 2, 2019 - Honey ‘as high in sugars as table sugar’
May 2, 2019 - Innovations to U.S. food system could help consumers in choosing healthy foods
May 2, 2019 - FDA Approves Mavyret (glecaprevir and pibrentasvir) as First Treatment for All Genotypes of Hepatitis C in Pediatric Patients
May 2, 2019 - Women underreport prevalence and intensity of their own snoring
May 2, 2019 - Concussion summit focuses on science behind brain injury
May 2, 2019 - Booker’s Argument For Environmental Justice Stays Within The Lines
May 2, 2019 - Cornell research explains increased metastatic cancer risk in diabetics
May 2, 2019 - Mount Sinai study provides fresh insights into cellular pathways that cause cancer
May 2, 2019 - Researchers to study link between prenatal pesticide exposures and childhood ADHD
May 2, 2019 - CoGEN Congress 2019: Speakers’ overviews
May 2, 2019 - A new strategy for managing diabetic macular edema in people with good vision
May 2, 2019 - Sagent Pharmaceuticals Issues Voluntary Nationwide Recall of Ketorolac Tromethamine Injection, USP, 60mg/2mL (30mg per mL) Due to Lack of Sterility Assurance
May 2, 2019 - Screen time associated with behavioral problems in preschoolers
May 2, 2019 - Hormone reduces social impairment in kids with autism | News Center
May 2, 2019 - Researchers synthesize peroxidase-mimicking nanozyme with low cost and superior catalytic activity
May 2, 2019 - Study results of a potential drug to treat Type 2 diabetes in children announced
May 2, 2019 - Multigene test helps doctors to make effective treatment decisions for breast cancer patients
May 2, 2019 - UNC School of Medicine initiative providing unique care to dementia patients
May 2, 2019 - Nestlé Health Science and VHP join forces to launch innovative COPES program for cancer patients
May 2, 2019 - Study examines how our brain generates consciousness and loses it during anesthesia
May 2, 2019 - Transition Support Program May Aid Young Adults With Type 1 Diabetes
May 2, 2019 - Study shows how neutrophils exacerbate atherosclerosis by inducing smooth muscle-cell death
May 2, 2019 - Research reveals complexity of how we make decisions
Study points to novel epigenetic target for Alzheimer’s Disease

Study points to novel epigenetic target for Alzheimer’s Disease

From left, Karolina J. Janczura, Claes Wahlestedt, M.D., Ph.D., and Claude-Henry Volmar, Ph.D. Credit: University of Miami

A research team at the University of Miami Miller School of Medicine’s Center for Therapeutic Innovation (CTI) has identified a novel epigenetic drug target to simultaneously normalize multiple deficits in Alzheimer’s disease (AD), the most common form of dementia in the elderly and the sixth leading cause of death in the U.S., according to the Alzheimer’s Association.

The study, titled “Inhibition of HDAC3 Reverses Alzheimer’s Disease-related Pathologies in vitro and in the 3xTg-AD Mouse Model,” was published on November 5 in the Proceedings of the National Academy of Sciences (PNAS). The researchers demonstrated that epigenetic “eraser” enzyme, histone deacetylase 3 (HDAC3) is connected to multiple Alzheimer’s disease hallmarks, including beta-amyloid (Aβ), hyperphosphorylated tau and several other aberrant genes.

“Importantly, none of the FDA-approved treatments available to date are efficacious at addressing these hallmarks, let alone multiple hallmarks,” said senior author Claes Wahlestedt, M.D., Ph.D., professor of psychiatry and behavioral sciences, associate dean for therapeutic innovation, and director of the Center for Therapeutic Innovation. His laboratory conducted the new study, which was supported by the National Institutes of Health and the State of Florida Department of Health (the Ed and Ethel Moore Alzheimer’s Disease Research Program).

Karolina J. Janczura, first author of the study, a Ph.D. candidate at the Center for Therapeutic Innovation and an American Heart Association predoctoral fellowship recipient, stated: “This was an incredibly rewarding experience. We were able to demonstrate that it is possible to re-program neuronal cell gene expression and thereby achieve a very striking reversal of deteriorating memory in our Alzheimer’s disease model.”

Claude-Henry Volmar, Ph.D., co-corresponding author, director of research laboratory at the Center for Therapeutic Innovation and associate director of Molecular Therapeutics Shared Resource at the Sylvester Comprehensive Cancer Center, added: “We discovered that treatment with RGFP-966, an experimental HDAC3 inhibitor drug, normalizes Alzheimer’s-like pathology in multiple cellular and animal models. Considering that the majority of clinical trials focused on traditional AD targets have failed to date, our group focused on the multifactorial aspect of the disease, and we hope our recent discovery will guide the development of AD therapeutics.”

“Further support of the potential role of HDAC3 in Alzheimer’s in this work comes from the fact that its inhibition in AD patient-derived neurons also resulted in reversal of AD phenotype,” Janczura said.

“Interestingly, a novel interaction between the protein tau and HDAC3 was discovered in this project, suggesting a possible role of HDAC3 in other tau-related pathologies in addition to AD,” Volmar said.

“Most importantly, this work endorses a multipronged approach to the treatment of AD and supports the broad therapeutic potential of a single epigenetic small molecule, bypassing the need for developing multiple drugs to be used in combination,” Wahlestedt said.


Explore further:
HDAC3 role in B-cell development

More information:
Karolina J. Janczura et al. Inhibition of HDAC3 reverses Alzheimer’s disease-related pathologies in vitro and in the 3xTg-AD mouse model, Proceedings of the National Academy of Sciences (2018). DOI: 10.1073/pnas.1805436115

Journal reference:
Proceedings of the National Academy of Sciences

Provided by:
University of Miami

Tagged with:

About author

Related Articles